



Date: 27th October, 2026

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra - Kurla Complex Bandra (East) Mumbai - 400 051 Stock Code : INDOCO-EQ	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, Mumbai - 400 001 Stock Code : 532612
--	--

Dear Sir/Madam,

Subject: Indoco's Clinical Research Organisation - AnaCipher receives approval from ANVISA Brazil for its clinical and bioanalytical facilities

Please find enclosed press release dated 27th October, 2026 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

**Thanking you,
Yours faithfully,
For Indoco Remedies Limited**

Ramanathan Hariharan
Digitally signed by
Ramanathan Hariharan
Date: 2026.10.27
15:27:10 +05'30'



**Ramanathan Hariharan
Company Secretary & Lead Legal**



PRESS RELEASE

Indoco's Clinical Research Organisation – AnaCipher, receives approval from ANVISA Brazil for its clinical and bioanalytical facilities

Mumbai, October 27, 2026: Indoco Remedies Ltd. has announced that its Clinical Research Organisation, AnaCipher has received approval from the **National Health Surveillance Agency of Brazil (Agência Nacional de Vigilância Sanitária – ANVISA)** for both, clinical and bioanalytical facilities. The inspection was conducted from March 30, 2026, to April 7, 2026.

With this approval, the CRO is authorised to conduct Bioavailability & Bioequivalence studies for submission to Brazil, along with associated bioanalytical support in accordance with ANVISA regulatory requirements.

Commenting on this development, **Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd.** said, "The approval reflects our CRO's robust quality management systems, qualified scientific and clinical teams, validated analytical capabilities, and adherence to international regulatory and Good Clinical Practice standards. It reinforces our commitment to global quality standards and enhances our ability to support pharmaceutical companies in conducting studies for Brazil and expanding across Latin America."

This approval further strengthens AnaCipher's international regulatory footprint and reinforces its position as a trusted partner for global clinical research programmes.

AnaCipher is a clinical research organisation headquartered in Hyderabad, India. The CRO provides bioequivalence and bioavailability studies, bioanalysis, clinical operations, regulatory affairs, data management, and biostatistics services to pharmaceutical companies worldwide. The CRO has been accredited by CDSCO, USFDA, WHO, EMA, UKMHRA, MoH-Oman & project-based approvals have been received from TPD-Canada, NMPA - China, MCC-South Africa & MoH-Iraq.

For more details visit: www.anaciphercro.com

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 175 million with human capital of over 6000 employees, including over 300 skilled scientists and field staff who are the strength of the organization.

The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 105 million prescriptions annually from over 2,39,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media enquiries please contact:

Tel. +91 22 62871000 | E-mail: corpcom@indoco.com